AR109625A1 - Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas - Google Patents

Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas

Info

Publication number
AR109625A1
AR109625A1 ARP160102969A ARP160102969A AR109625A1 AR 109625 A1 AR109625 A1 AR 109625A1 AR P160102969 A ARP160102969 A AR P160102969A AR P160102969 A ARP160102969 A AR P160102969A AR 109625 A1 AR109625 A1 AR 109625A1
Authority
AR
Argentina
Prior art keywords
methods
tigit
proteins
selectly
abp
Prior art date
Application number
ARP160102969A
Other languages
English (en)
Spanish (es)
Inventor
William Winston
Daniel Hicklin
Nels P Nielson
Cynthia S Dugan
Original Assignee
Potenza Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Potenza Therapeutics Inc filed Critical Potenza Therapeutics Inc
Publication of AR109625A1 publication Critical patent/AR109625A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ARP160102969A 2015-10-01 2016-09-29 Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas AR109625A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562235990P 2015-10-01 2015-10-01

Publications (1)

Publication Number Publication Date
AR109625A1 true AR109625A1 (es) 2019-01-09

Family

ID=57113807

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102969A AR109625A1 (es) 2015-10-01 2016-09-29 Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas

Country Status (26)

Country Link
US (3) US9713641B2 (tr)
EP (1) EP3356413B1 (tr)
JP (1) JP7023233B2 (tr)
KR (1) KR20180068990A (tr)
CN (1) CN108368176B (tr)
AR (1) AR109625A1 (tr)
AU (1) AU2016331052B2 (tr)
BR (1) BR112018006531A2 (tr)
CA (1) CA3000404A1 (tr)
CO (1) CO2018004743A2 (tr)
DK (1) DK3356413T3 (tr)
ES (1) ES2910027T3 (tr)
HK (1) HK1253235A1 (tr)
HU (1) HUE058755T2 (tr)
IL (1) IL258394B (tr)
MX (1) MX2018003898A (tr)
MY (1) MY192226A (tr)
PH (1) PH12018500714A1 (tr)
PL (1) PL3356413T3 (tr)
PT (1) PT3356413T (tr)
RU (2) RU2729379C1 (tr)
SG (1) SG10201912736UA (tr)
TW (1) TWI778943B (tr)
UA (1) UA125062C2 (tr)
WO (1) WO2017059095A1 (tr)
ZA (2) ZA201904675B (tr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2016134335A2 (en) 2015-02-19 2016-08-25 Compugen Ltd. Pvrig polypeptides and methods of treatment
PT3295951T (pt) 2015-02-19 2020-07-21 Compugen Ltd Anticorpos anti-pvrig e métodos de utilização
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
SG10201913276WA (en) 2015-09-01 2020-02-27 Agenus Inc Anti-pd-1 antibodies and methods of use thereof
PL3356413T3 (pl) 2015-10-01 2022-04-19 Potenza Therapeutics, Inc. Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
KR20230091191A (ko) 2016-05-27 2023-06-22 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CA3032897A1 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
AU2017313405B2 (en) * 2016-08-17 2024-09-26 Compugen Ltd. Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
WO2018102536A1 (en) 2016-11-30 2018-06-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
JOP20190203A1 (ar) * 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018200430A1 (en) 2017-04-26 2018-11-01 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
KR20180120893A (ko) * 2017-04-28 2018-11-07 재단법인 목암생명과학연구소 Pvr 및 4-1bbl을 포함하는 융합단백질 및 이의 용도
RS64576B1 (sr) * 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
KR20200021474A (ko) 2017-06-01 2020-02-28 컴퓨젠 엘티디. 삼중 조합 항체 치료제
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
EP3484925B1 (en) 2017-07-27 2020-05-27 iTeos Therapeutics SA Anti-tigit antibodies
MX2020001270A (es) 2017-07-31 2020-09-22 Trishula Therapeutics Inc Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
EP3689909A4 (en) * 2017-09-29 2021-12-29 Jiangsu Hengrui Medicine Co., Ltd. Tigit antibody, antigen-binding fragment thereof, and medical use thereof
US11725056B2 (en) * 2017-10-03 2023-08-15 Cedars-Sinai Medical Center Methods for targeting the immune checkpoint PD1 pathway for treating pulmonary fibrosis
GB2569144B (en) * 2017-12-06 2021-06-16 Proimmune Ltd Method for screening the activity of mutated expressed polypeptides
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
SG11202004158QA (en) * 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
TW202400654A (zh) * 2017-12-30 2024-01-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
KR20200109313A (ko) * 2018-01-15 2020-09-22 난징 레전드 바이오테크 씨오., 엘티디. Tigit에 대한 항체 및 이의 변이체
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
KR102224556B1 (ko) * 2018-02-06 2021-03-09 아이-맵 바이오파마 유에스 리미티드 Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
MX2020008795A (es) 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
EP3774840A1 (en) 2018-03-27 2021-02-17 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
SG11202011461TA (en) 2018-06-01 2020-12-30 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
KR20210040827A (ko) * 2018-07-25 2021-04-14 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 항 tigit 항체 및 그 용도
BR112021003156A2 (pt) 2018-08-23 2021-05-11 Seagen, Inc. composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
TWI824020B (zh) 2018-09-26 2023-12-01 日商安斯泰來製藥股份有限公司 藉由腫瘤溶解性牛痘病毒與免疫檢查點抑制劑併用之癌症療法以及用於其之醫藥組合物及組合醫藥
JP2022519118A (ja) * 2019-02-01 2022-03-18 ノヴァロック バイオセラピューティクス， リミテッド 抗クローディン１８抗体及びそれらの使用の方法
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
CN111744013B (zh) * 2019-03-29 2022-07-26 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
US20220220430A1 (en) 2019-05-23 2022-07-14 Bristol-Myers Squibb Company Methods of monitoring cell culture media
KR102332847B1 (ko) * 2019-06-13 2021-12-01 주식회사 녹십자 Tigit에 대한 항체 및 이의 용도
EP3993832A4 (en) * 2019-07-03 2023-10-18 Crystal Bioscience Inc. ANTI-CD38 ANTIBODIES AND METHOD OF USE THEREOF
EP4001308A4 (en) * 2019-07-15 2023-08-23 Shanghai Junshi Biosciences Co., Ltd. ANTI-TIGIT ANTIBODIES AND THEIR APPLICATION
CN112239507A (zh) * 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20220290179A1 (en) 2019-08-29 2022-09-15 Astellas Pharma Inc. Genetically engineered oncolytic vaccinia viruses and methods of uses thereof
TWI764291B (zh) 2019-09-24 2022-05-11 財團法人工業技術研究院 抗tigit抗體及使用方法
WO2021093849A1 (en) * 2019-11-14 2021-05-20 Wuxi Biologics (Shanghai) Co., Ltd. A novel antibody against tigit
JP2023502725A (ja) * 2019-11-21 2023-01-25 ユニティ バイオテクノロジー インコーポレイテッド Ｔｉｅ－２に対する抗体および使用方法
WO2021113831A1 (en) 2019-12-05 2021-06-10 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
CN113087806B (zh) * 2019-12-31 2022-09-06 华东师范大学 靶向多种肿瘤的新型car-t细胞及其制备和方法
CN110818795B (zh) * 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
CN113563470B (zh) 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
WO2022076318A1 (en) 2020-10-05 2022-04-14 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN118591557A (zh) * 2022-01-24 2024-09-03 原启生物科技(上海)有限责任公司 靶向tigit的抗原结合蛋白及其用途
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
AU2023236289A1 (en) 2022-03-15 2024-08-15 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
TW202409083A (zh) 2022-05-02 2024-03-01 美商阿克思生物科學有限公司 抗-tigit抗體及其用途
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050809A1 (en) 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
EP2085096A3 (en) 2002-09-11 2009-08-12 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CN1791433B (zh) 2003-03-24 2010-05-26 斯克里普斯研究学院 抗肿瘤生长的dna疫苗及其使用方法
EP3214095B1 (en) 2005-05-12 2019-12-11 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
JP5372500B2 (ja) * 2005-06-17 2013-12-18 トレラクス リクイデーティング トラスト Ｉｌｔ３結合分子およびその使用
WO2007073478A2 (en) 2005-12-19 2007-06-28 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
BRPI0812913B8 (pt) 2007-06-18 2021-05-25 Merck Sharp & Dohme anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR20180132156A (ko) * 2008-04-09 2018-12-11 제넨테크, 인크. 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
EP2388336A1 (en) 2010-05-19 2011-11-23 Signature Diagnostics AG Method and kits for diagnosing colorectal cancer
EP2580238A1 (en) 2010-06-09 2013-04-17 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
BR112013001175A2 (pt) 2010-07-16 2017-07-04 Adimab Llc bibliotecas de anticorpos
BR112013010099B1 (pt) 2010-10-26 2021-08-10 Mars, Incorporated Boronatos como inibidores de arginase
DE102011005235B4 (de) 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
MX2014014951A (es) 2012-06-06 2015-03-13 Oncomed Pharm Inc Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
PT2925350T (pt) 2012-12-03 2019-03-25 Bristol Myers Squibb Co Melhoria da atividade anticancerosa de proteínas de fusão de fc imunomoduladoras
AR093788A1 (es) 2012-12-04 2015-06-24 Oncomed Pharm Inc Inmunoterapia con agentes de enlace
US10156574B2 (en) 2013-04-29 2018-12-18 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
MY183503A (en) * 2013-07-16 2021-02-23 Genentech Inc Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
MY198017A (en) 2014-08-19 2023-07-26 Merck Sharp & Dohme Anti-tigit antibodies
AU2015343494A1 (en) * 2014-11-06 2017-04-27 Genentech, Inc. Combination therapy comprising OX40 binding agonists and TIGIT inhibitors
BR112017013385A2 (pt) 2014-12-23 2018-02-06 Bristol-Myers Squibb Company anticorpos para tigit
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
ES2924071T3 (es) 2015-09-02 2022-10-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
CN113956358A (zh) 2015-09-25 2022-01-21 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
CN106554347B (zh) 2015-09-25 2020-10-30 浙江博生医药有限公司 Egfr激酶抑制剂及其制备方法和应用
PL3356413T3 (pl) 2015-10-01 2022-04-19 Potenza Therapeutics, Inc. Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها

Also Published As

Publication number Publication date
ES2910027T3 (es) 2022-05-11
UA125062C2 (uk) 2022-01-05
US20170165366A1 (en) 2017-06-15
IL258394B (en) 2022-04-01
JP7023233B2 (ja) 2022-02-21
BR112018006531A2 (pt) 2018-12-11
TW201718636A (zh) 2017-06-01
US11590224B2 (en) 2023-02-28
TWI778943B (zh) 2022-10-01
RU2729379C1 (ru) 2020-08-06
US20170340735A1 (en) 2017-11-30
HUE058755T2 (hu) 2022-09-28
JP2018533371A (ja) 2018-11-15
ZA201904675B (en) 2021-02-24
IL258394A (en) 2018-05-31
MY192226A (en) 2022-08-10
CO2018004743A2 (es) 2018-11-30
MX2018003898A (es) 2018-12-17
AU2016331052A1 (en) 2018-04-26
RU2020124191A (ru) 2020-08-27
CN108368176A (zh) 2018-08-03
CN108368176B (zh) 2022-06-07
KR20180068990A (ko) 2018-06-22
US10507244B2 (en) 2019-12-17
EP3356413B1 (en) 2022-01-05
WO2017059095A1 (en) 2017-04-06
PL3356413T3 (pl) 2022-04-19
EP3356413A1 (en) 2018-08-08
US20200101158A1 (en) 2020-04-02
DK3356413T3 (da) 2022-04-11
US9713641B2 (en) 2017-07-25
HK1253235A1 (zh) 2019-06-14
AU2016331052B2 (en) 2023-08-03
PH12018500714A1 (en) 2018-10-15
CA3000404A1 (en) 2017-04-06
ZA202004919B (en) 2022-07-27
PT3356413T (pt) 2022-04-04
SG10201912736UA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
CO2020001983A2 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anticd39
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
ECSP17041865A (es) Anticuerpos anti-cd47 y usos de los mismos
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CR20180105A (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
CO2019009612A2 (es) Proteinas de unión a antígeno anti-tigit y métodos de uso de las mismas
GT201700112A (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
CL2023002048A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
AR104847A1 (es) Formulación de anticuerpo anti-cgrp
GT201700188A (es) Anticuerpos contra tau y sus usos
CO2019006424A2 (es) Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas
DOP2017000052A (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
CO2017000558A2 (es) Variantes de proteínas de unión al factor h
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
CL2019003557A1 (es) Anticuerpos anti-trkb.
CL2017003311A1 (es) Proteínas de fijación multiespecífica.
AR112904A1 (es) Proteínas de unión a antígenos anti-gitr y métodos para el uso de las mismas
AR105714A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos